USA flag logo/image

An Official Website of the United States Government

SBIR Phase II: Gene signature screening for Pancreatic Cancer Therapeutics from…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
1127476
Solicitation Year:
2012
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
NUVOGEN RESEARCH, LLC
PO Box 64326 Tucson, AZ 85728-0000
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: SBIR Phase II: Gene signature screening for Pancreatic Cancer Therapeutics from Sonoran Desert extracts
Agency: NSF
Contract: 1127476
Award Amount: $364,588.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase II project is to address the high lethality of pancreatic cancer. Screening has begun with Phase IB funding, of natural products from the Sonoran Desert that have produced other promising drug candidates, testing effects on human pancreatic cancer cells. The objective of Phase II is to develop a drug candidate that alters expression of selected pancreatic cancer-related genes and that kills pancreatic cancer cells that express those genes. The drug candidates will be developed using a personalized medicine approach. The gene expression profiles (or genomics patterns) for many different pancreatic cancer tumors will be matched to the effects on genomics produced by the drug. This personalized approach could translate directly to clinical trials to pre-select patients most likely to respond to the drug. The broader impacts of this research are first to reduce deaths due to pancreatic cancer, which ranked fourth among the leading causes of cancer death with 35,240 deaths in the US in 2009. The 5-year survival rate for patients with metastatic disease is 1.8%. The societal impact and commercial value of targeting such a lethal disease are very high. Further, the personalized medicine approach to drug development will impact many oncology projects. The idea of matching each patient's genomics patterns with each drug that targets that pattern will be critical. Each kind of cancer is not one disease, but a wide spectrum of accumulated genomics changes that have to be addressed individually.

Principal Investigator:

Richard M. Kris
5202705209
rkris@nuvogenresearch.com

Business Contact:

Richard M. Kris
5202705209
rkris@nuvogenresearch.com
Small Business Information at Submission:

Nuvogen Research
PO Box 64326 Tucson, AZ 85728-0000

EIN/Tax ID: 860897386
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No